OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., May 24, 2022 (GLOBE NEWSWIRE) --  OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022.

OrthoPediatrics to Participate in The JMP Securities Life Sciences Conference

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Matt Bacso - IR, Gilmartin Group David Bailey - President and CEO Fred Hite - CFO and COO Conference Call Participants Matthew O'Brien - Piper Sandler Samuel Brodovsky - Truist Securities Mike Matson - Needham & Company Ryan Zimmerman - BTIG Dave Turkaly - JMP Securities Operator Welcome to the Q1 2022 OrthoPediatrics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode.

OrthoPediatrics Corp. (KIDS) CEO David Bailey on Q1 2022 Earnings Call Transcript

First Quarter 2022 Revenue Increased 9% Year-over-Year First Quarter 2022 Revenue Increased 9% Year-over-Year

OrthoPediatrics Corp. Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

WARSAW, Ind., April 18, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company is scheduled to release its first quarter 2022 financial results on Wednesday, May 4, 2022, after the market closes.

OrthoPediatrics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022

Expands portfolio with a patented, non-operative solution for the treatment of clubfoot Expands portfolio with a patented, non-operative solution for the treatment of clubfoot

OrthoPediatrics Corp. Announces Acquisition of MD Orthopaedics

OrthoPediatrics Corp. (KIDS) CEO David Bailey on Q4 2021 Results - Earnings Call Transcript

Fourth Quarter 2021 Revenue Increased 31% Year-over-Year 2021 Revenue Increased 38% Year-over-Year

OrthoPediatrics Corp. Reports Fourth Quarter and Record Full Year 2021 Financial Results

WARSAW, Ind., Feb. 25, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced it was recently named one of the 2022 Best Places to Work in Indiana. This is the 6th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce and Best Companies Group.

OrthoPediatrics Corp. Named One of the 2022 Best Places to Work in Indiana

Company's partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatment Company's partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatment

OrthoPediatrics Corp. Celebrates 1,000th Case with FIREFLY® Pedicle Screw Navigation Guides

WARSAW, Ind., Feb. 01, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company is scheduled to release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, after the market closes.

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

WARSAW, Ind., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.

OrthoPediatrics Announces Preliminary Unaudited Revenue for the Fourth Quarter & Full-Year 2021

WARSAW, Ind.--(BUSINESS WIRE)-- #MDR--Telos Partners LLC, a subsidiary of OrthoPediatrics Corporation (NASDAQ: KIDS), specializing in the delivery of regulatory, reimbursement, and clinician adoption and other consulting services to the orthopedic, spine, and wound care industries, is pleased to welcome Scott Day to the position of Senior VP and General Manager. Scott assumes this role following the completion of Jason Inzana's time leading the Telos organization. Since being acquired by OrthoPediatri

Telos Partners LLC Welcomes Industry Veteran Scott Day as Senior VP and General Manager to Accelerate Growth Strategy

Intuitive Surgical

Pfizer

Here are three stocks sure to pique the interest of that special someone.

3 Last-Minute Healthcare Stocking Stuffers

WARSAW, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support as a Double-Diamond sponsor of the International Pediatric Orthopaedic Symposium (IPOS), which took place December 7 – 11 in Orlando, Florida. Over 400 pediatric orthopedic surgeons attended the meeting. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons.

OrthoPediatrics Corp. Continued Double-Diamond Support of International Pediatric Orthopaedic Symposium (IPOS)

WARSAW, Ind., Nov. 22, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the release of a fireside chat webcast in connection with the 33rd Annual Piper Sandler Virtual Healthcare Conference. The fireside chat includes participation by Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer. OrthoPediatrics will be participating in 1x1 investor meetings on December 1, 2021. Meetings can be requested exclusively via Piper Sandler

OrthoPediatrics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

OrthoPediatrics Corp. (KIDS) CEO David Bailey on Q3 2021 Results - Earnings Call Transcript

Third Quarter 2021 Revenue Increased 13% Year-over-Year Third Quarter 2021 Revenue Increased 13% Year-over-Year

OrthoPediatrics Corp. Reports Third Quarter 2021 Financial Results

WARSAW, Ind., Oct. 26, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Executive Chairman, are scheduled to participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021.

OrthoPediatrics to Participate in the Stifel 2021 Virtual Healthcare Conference

WARSAW, Ind., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has been awarded a Silver metal designation as part of the “COVID Stops Here” campaign for achieving an 80% plus vaccination rate at its Indiana headquarters.

OrthoPediatrics Corp. Recognized in COVID Stops Here Campaign

WARSAW, Indiana, Oct. 13, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary revenue for the third quarter ended September 30, 2021 and provided a related business update.

OrthoPediatrics Corp. Announces Preliminary Unaudited Revenue for the Third Quarter 2021 and Reiterates 2021 Revenue Guidance

WARSAW, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support for the American Academy for Cerebral Palsy and Developmental Medicine (“AACPDM”), which will take place virtually October 6th – 9th.

OrthoPediatrics Corp. Continues Support of Autumn Surgical Society Meetings

Orthofix International

SeaSpine Holdings

Stryker

Zimmer Biomet Hlds

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

OrthoPediatrics Corp (NASDAQ: KIDS) entered into a distribution agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE) for the 7D Surgical FLASH Navigation platform.  Under the 5-year exclusive agreement, OrthoPediatrics will distribute the platform for pediatric application.

OrthoPediatrics, SeaSpine Ink Distribution Pact For Image Guidance System

Enables OrthoPediatrics to Further Address Full Patient Continuum of Care for Pediatric Orthopedic Surgeons with Market-Leading, Radiation-Free Navigation Technology Enables OrthoPediatrics to Further Address Full Patient Continuum of Care for Pediatric Orthopedic Surgeons with Market-Leading, Radiation-Free Navigation Technology

OrthoPediatrics Announces Entry into a Distribution Agreement with SeaSpine to Exclusively Distribute the 7D Surgical FLASH Navigation Platform for Pediatric Applications

Fred Hite, Coo And Cfo at Orthopediatrics (NASDAQ:KIDS), made a large insider sell on September 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Hite sold 5,000 shares of Orthopediatrics at a price of $71.5 per share.

News for OrthoPediatrics Stock (KIDS)